Companies Owned by Brian Armstrong: Stakes, Investments & Exits

Coinbase earns revenue from activity across digital-asset trading, custody, subscriptions, stablecoin-related services and institutional infrastructure. That business is exposed to transaction volume and customer demand, but its 2026 strategy seeks a wider base than Bitcoin spot fees alone. The company reported that 88% of second-quarter net revenue came from activities outside Bitcoin spot trading. For Armstrong, the economic proposition is an integrated financial platform whose customers can use several services, with different fee streams attached to the same trusted relationship.

Deribit broadens the derivatives offering rather than creating an unrelated personal business. Coinbase completed the acquisition in August 2025, adding an established options venue and associated institutional demand. We see a more extensive trading franchise, while recognizing that derivatives introduce their own liquidity, collateral and operational requirements. Product breadth can reduce dependence on one source of fees, but a broad crypto-market contraction can still affect activity across several services at the same time.

ResearchHub Technologies addresses a different coordination problem. The platform supports open publication, paid peer review and funding of scientific work, with ResearchCoin used to reward contributions. Its commercial challenge is to attract researchers and funders while maintaining research quality and useful incentives. A token can support participation without establishing the value of Armstrong's company equity. The platform's success depends on scientific adoption and credible workflows, rather than simply the trading price or visibility of a crypto asset associated with it.

NewLimit makes epigenetic reprogramming medicines, with a $435 million Series C announced in June 2026. This is a research-intensive biotechnology model with a much longer path to product revenue than an exchange transaction or paid platform service. Armstrong contributes founder capital and board involvement, while the scientific organization must produce evidence and navigate development milestones. His businesses therefore combine financial infrastructure, research coordination and experimental therapeutics, with the latter two adding new demands on capital and expertise beyond the market cycle that shaped Coinbase.

Armstrong's 49.6% disclosed Coinbase voting power in the March 2026 ownership snapshot is close to half, but it is not a simple statement that he owns half the company's economics. Class B shares carry twenty votes each, compared with one for Class A. The beneficial ownership calculation also includes exercisable options and Class B shares held by the Ehrsam trust for which he serves as trustee. We separate control over a vote from the right to retain the economic benefits of that security.

The proxy lists another 18.9% of votes with independently administered trusts established by Armstrong. Those trusts cannot automatically be added to his personal voting authority simply because they bear his name. The distinction becomes important in succession and family planning: creating a trust can preserve benefits for particular beneficiaries while moving decision rights to another trustee. Coinbase's public governance therefore requires attention to the named holder, the trustee and the legal powers assigned under each arrangement, rather than aggregation by surname.

At ResearchHub Technologies, Armstrong's founder, chief-executive and board positions establish a direct operating relationship. The company remains separate from Coinbase even though his public-company biography discloses the role. ResearchHub's platform decisions and finances belong to its own organization. Coinbase users do not acquire ResearchHub ownership merely by holding accounts, and Coinbase shareholders do not automatically receive Armstrong's personal economic interest in the scientific platform. Common leadership provides a connection without collapsing the companies into one legal business.

NewLimit gives him another form of influence. He is a co-founder, investor and director, while Jacob Kimmel leads the company as chief executive and president. The presence of institutional investors following the 2026 Series C adds other capital providers and governance interests. Armstrong can support the venture's direction without being its sole owner or daily scientific manager. Across his holdings, authority ranges from a powerful public-company voting position to an active private operating role and a biotechnology board investment with shared responsibilities.

NewLimit illustrates Armstrong's willingness to invest outside software and financial markets. The company raised a $130 million Series B in May 2025 with his participation, then secured another $435 million through its June 2026 Series C. Those successive financings substantially expanded its resources for epigenetic-reprogramming medicines. They also changed the capitalization against which earlier investors participate. We judge the opportunity through scientific progress and the resources needed to reach the next development stage, rather than treating money raised as a return already earned by founders.

The $3.1 billion Series C valuation reported by Forbes is a company-level financing benchmark. It does not reveal the cash value Armstrong could realize from his shares or the preferences attached to the newest securities. Biotechnology funding must cover research, development personnel and the work needed to move a candidate toward human testing. A larger round can reduce near-term financing pressure while raising expectations about the scale of an eventual success. His personal investment amount in that round is a separate matter from the total announced financing.

ResearchHub Technologies offers a different experiment in allocating capital. Paying reviewers and rewarding research contributions with ResearchCoin aims to improve incentives around scientific work. Its return drivers include adoption, quality and the willingness of funders to support work through the platform. The existence of an incentive token does not establish an entitlement to company profits. Armstrong's equity exposure and any token-related interests require separate treatment, particularly when judging how sustainable platform activity is without relying on speculative trading demand.

Coinbase's Deribit purchase is an investment made by the public company under Armstrong's leadership. It expanded derivatives capabilities and brought an existing customer base into the group. That transaction can improve the value of his Coinbase holding if integration and earnings justify the acquisition cost. It does not create a separate personal purchase of Deribit. The Bel Air estate adds yet another allocation, committing $133 million at acquisition to residential property with much less immediate divisibility than publicly traded stock.

UniversityTutor provides a documented early exit in Armstrong's own business history. His project page identifies the tutoring directory as acquired in 2014. The transaction ended that venture's status as an independently held founder business, while Coinbase remained his principal operating focus. The published history does not establish a personal sale receipt that can be assigned to him. We distinguish the completion of an acquisition from the size of any distribution received by a particular shareholder after other claims and transaction terms.

Coinbase's April 2021 direct listing created a much larger public liquidity route. It allowed existing holders to trade eligible shares while Armstrong continued as chief executive and retained high-vote securities. A listing is not equivalent to selling the whole company to a buyer. Subsequent individual stock sales can release capital and reduce concentration without eliminating the founder's continuing exposure. His 2026 ownership disclosure confirms that substantial voting and economic interests remained after the public-market transition.

Deribit's August 2025 acquisition is an exit for its former owners and a purchase by Coinbase. It belongs on the buyer side of Armstrong's corporate capital-allocation record, rather than being presented as money paid to him for selling a personal business. The future return reaches him through his interest in Coinbase and any effect on its valuation. That distinction also applies to Coinbase Ventures, whose portfolio realizations belong first to the listed company rather than directly to its chief executive.

NewLimit and ResearchHub remain separate current interests, with no completed founder exit established by their recent activity. NewLimit's 2026 financing supplies development capital instead of proving personal liquidity for Armstrong. A later sale, public offering or secondary transaction would depend on the terms of the relevant securities and any transfer restrictions. His transaction history consequently combines an early tutoring-business acquisition, continuing public-share liquidity and corporate expansion, while the scientific ventures remain investments whose eventual financial outcomes are still developing.